Ifosfamide or trofosfamide in patients with intraocular lymphoma

Journal of Neuro-Oncology

Volumn 93, Issue 2, 2009, Pages 213-217

  Jahnke, Kristoph ^a   Thiel, Eckhard ^a   Bechrakis, Nikolaos E ^a   Willerding, Gregor ^a   Kraemer, Dale F ^b,c   Fischer, Lars ^a   Korfel, Agnieszka ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Ifosfamide; Intraocular lymphoma; Primary CNS lymphoma; Trofosfamide

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; TOPOTECAN; TROFOSFAMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOCYTOMA; INTRAOCULAR TUMOR; LARGE CELL LYMPHOMA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; EYE NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LYMPHOMA; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; VITRECTOMY;

EID: 67349239314     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9761-8     Document Type: Article

References (23)

1. Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M, Cavalli F, International Extranodal Lymphoma Study Group (IELSG) (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531-538. doi: 10.1093/annonc/mdf080
2. Fine HA, Mayer RJ (1993) Primary central nervous system lymphoma. Ann Intern Med 119:1093-1104
3. Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE (2008) Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 71:1355-1360. doi: 10.1212/01.wnl.0000327672.04729.8c
4. Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Blay JY, Ferreri AJM, Omuro A, Abrey LE (2007) Primary intraocular lymphoma (PIOL): An International Primary CNS Lymphoma Collaborative Group Report. Ann Oncol 18:1851-1855. doi: 10.1093/annonc/mdm340
5. Rodeghiero F, Elice F (2003) Ifosfamide in hematological malignancies of adults. Oncology 65(2):85-93. doi: 10.1159/000073367
6. Sneller V, Armitage J (2003) Current role and future perspectives for ifosfamide in the treatment of malignant non-Hodgkin's lymphoma - results from an expert meeting. Ann Oncol 14(1):i1-i3. doi: 10.1093/ annonc/mdg701
7. Wagner A, Hempel G, Boos J (1997) Trofosfamide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 8:419-431. doi: 10.1097/00001813-199706000-00002
8. Yule SM, Price L, Pearson AD, Boddy AV (1997) Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 3:1985-1992
9. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489-4495. doi: 10.1200/JCO.2003.04.056
10. Jahnke K, Wagner T, Bechrakis NE, Willerding G, Coupland SE, Fischer L, Thiel E, Korfel A (2005) Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Ann Oncol 16:1974-1978. doi: 10.1093/annonc/mdi409
11. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, CNS International Primary Lymphoma Collaborative Group (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043. doi: 10.1200/JCO.2005.13.524
12. Kaplan EL, Meier P (1958) Non-parametric estimations from incomplete observations. J Am Stat Assoc 53:457-481. doi: 10.2307/2281868
13. Buggage RR, Chan CC, Nussenblatt RB (2001) Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 13:137-142. doi: 10.1097/00001622-200105000-00001
14. Char DH, Ljung BM, Miller T, Phillips T (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95:625-630
15. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709-1716. doi: 10.1016/S0161-6420(02)01125-9
16. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711-715
17. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21:1044-1049. doi: 10.1200/JCO.2003.03.036
18. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM (2004) Ocular presentation of primary central nervous system lymphoma: Diagnosis and treatment. Br J Haematol 126:202-208. doi: 10.1111/ j.1365-2141.2004.05028.x
19. Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, Coupland SE (2006) Intraocular lymphoma 2000-2005: Results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 244:663-669. doi: 10.1007/s00417-005-0138-9
20. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM (1993) The clinical spectrum of ocular lymphoma. Cancer 72:843-849. doi:10.1002/ 1097-0142(19930801)72:3<843::AID-CNCR2820720333>3.0.CO;2-#
21. Rockwood EJ, Zakov ZN, Bay JW (1984) Combined malignant lymphoma of the eye and CNS (reticulum-cell sarcoma). Report of three cases. J Neurosurg 61:369-374
22. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272. doi: 10.1200/ JCO.2003.09.139
23. Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O'Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD (2007) Intraocular use of rituximab. Eye 21:1524-1527. doi: 10.1038/sj.eye.6702804